The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

The adoption of the FAIR model was pivotal in transforming our cybersecurity strategy into a measurable, business-aligned ...

Galapagos offers deep value with €3B cash, a focused M&A strategy, and new leadership. Click here to read an analysis of GLPG ...

As part of conversations between AI healthcare leaders on the podcast AI Amplified this year, a clear picture emerged of where artificial intelligence is genuinely transforming healthcare — and where ...

Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management ...

Kalaris Therapeutics offers differentiated approach to neovascular AMD with its lead candidate TH103. Click here to read my ...

With strong 1-year returns and upside potential, Ventyx Biosciences, Inc. (NASDAQ:VTYX) secures a spot on our list of the 12 ...

Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 ...

Following the clinical success of new agents like nerandomilast, the next critical steps for managing ILD involve dismantling financial and geographical barriers to access, and rigorously integrating ...

ZURZUVAE, also known as zuranoline, is a 14-day treatment but clinical trials have reported to show improvements as early as ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind” or the 'Company'), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived ...

Researchers say the drug likely increases the risk of serious side effects, including heart disease, and that its potential ...